Literature DB >> 32909054

Amide signal intensities may be reduced in the motor cortex and the corticospinal tract of ALS patients.

Zhuozhi Dai1,2, Sanjay Kalra3, Dennell Mah3, Peter Seres2, Hongfu Sun4, Renhua Wu5, Alan H Wilman6.   

Abstract

OBJECTIVES: The aim of the study is to assess amide concentration changes in ALS patients compared with healthy controls by using quantitative amide proton transfer (APT) and multiparameter magnetic resonance imaging, and testing its correlation with clinical scores.
METHODS: Sixteen ALS patients and sixteen healthy controls were recruited as part of the Canadian ALS Neuroimaging Consortium, and multimodal magnetic resonance imaging was performed at 3 T, including APT and diffusion imaging. Lorentz fitting was used to quantify the amide effect. Clinical disability was evaluated using the revised ALS functional rating scale (ALSFRS-R), and its correlation with image characteristics was assessed. The diagnostic performance of different imaging parameters was evaluated with receiver operating characteristic analysis.
RESULTS: Our results showed that the amide peak was significantly different between the motor cortex and other gray matter territories within the brain of ALS patients (p < 0.001). Compared with controls, amide signal intensities in ALS were significantly reduced in the motor cortex (p < 0.001) and corticospinal tract (p = 0.046), while abnormalities were not detected using routine imaging methods. There was no significant correlation between amide and ALSFRS-R score. The diagnostic accuracy of the amide peak was superior to that of diffusion imaging.
CONCLUSIONS: This study demonstrated changes of amide signal intensities in the motor cortex and corticospinal tract of ALS patients. KEY POINTS: • The neurodegenerative disease amyotrophic lateral sclerosis (ALS) has a lack of objective imaging indicators for diagnosis and assessment. • Analysis of amide proton transfer imaging revealed changes in the motor cortex and corticospinal tract of ALS patients that were not visible on standard magnetic resonance imaging. • The diagnostic accuracy of the amide peak was superior to that of diffusion imaging.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Brain; Magnetic resonance imaging

Mesh:

Substances:

Year:  2020        PMID: 32909054     DOI: 10.1007/s00330-020-07243-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  66 in total

1.  Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: A voxel-wise meta-analysis of voxel based morphometry studies.

Authors:  Zhiye Chen; Lin Ma
Journal:  Amyotroph Lateral Scler       Date:  2010-10-07

2.  The "Motor Band Sign:" Susceptibility-Weighted Imaging in Amyotrophic Lateral Sclerosis.

Authors:  Santanu Chakraborty; Aparna Gupta; Thanh Nguyen; Pierre Bourque
Journal:  Can J Neurol Sci       Date:  2015-05-14       Impact factor: 2.104

3.  A revision of the El Escorial criteria - 2015.

Authors:  Albert Ludolph; Vivian Drory; Orla Hardiman; Imaharu Nakano; John Ravits; Wim Robberecht; Jeremy Shefner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-06-29       Impact factor: 4.092

4.  Drug therapy: On the treatment trail for ALS.

Authors:  Andrew Scott
Journal:  Nature       Date:  2017-10-18       Impact factor: 49.962

Review 5.  Amyotrophic lateral sclerosis.

Authors:  Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

6.  Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study.

Authors:  Maarten Schrooten; Charlotte Smetcoren; Wim Robberecht; Philip Van Damme
Journal:  Ann Neurol       Date:  2011-03-17       Impact factor: 10.422

7.  Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis.

Authors:  Jing Han; Lin Ma
Journal:  J Magn Reson Imaging       Date:  2010-02       Impact factor: 4.813

8.  Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models.

Authors:  Alex McCampbell; Tracy Cole; Amy J Wegener; Giulio S Tomassy; Amy Setnicka; Brandon J Farley; Kathleen M Schoch; Mariah L Hoye; Mark Shabsovich; Linhong Sun; Yi Luo; Mingdi Zhang; Nicole Comfort; Bin Wang; Jessica Amacker; Sai Thankamony; David W Salzman; Merit Cudkowicz; Danielle L Graham; C Frank Bennett; Holly B Kordasiewicz; Eric E Swayze; Timothy M Miller
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

Review 9.  Quantifying disease progression in amyotrophic lateral sclerosis.

Authors:  Neil G Simon; Martin R Turner; Steve Vucic; Ammar Al-Chalabi; Jeremy Shefner; Catherine Lomen-Hoerth; Matthew C Kiernan
Journal:  Ann Neurol       Date:  2014-09-30       Impact factor: 10.422

Review 10.  Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis.

Authors:  Ricarda A L Menke; Federica Agosta; Julian Grosskreutz; Massimo Filippi; Martin R Turner
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.